Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects

Acute Pain Clinical Trial

Official title:

Study of the Efficacy of Co-administration of an NSAID With a Dopamine Agonist in the Alleviation of Acute Cutaneous Inflammatory Pain in Healthy Subjects

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02116790
• Other study ID #: STU00083465
• Secondary ID: R01DE022746
• Status: Withdrawn
• Phase: Phase 2
• First received: February 17, 2014
• Last updated: October 9, 2014
• Start date: May 2014
• Est. completion date: January 2015

Study information

• Verified date: October 2014
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Findings from the investigator's lab and others' show the involvement of the brain's mesolimbic circuitry in pain perception and evaluation, as well as during the transition from acute to chronic pain states in both humans and animals. Dopamine (DA) is one of the main neurotransmitters in this circuitry, and it is possible it could have an intimate role in pain processing, chronicity, and related anatomical and functional neuroplasticity. In this study, the investigators first need to know if the combination of l-dopa and Naproxen is safe and efficacious in humans with acute pain, and if so, at what doses. For the present study, healthy pain-free participants will be injected with a small bolus of capsaicin subcutaneously to induce acute cutaneous inflammatory pain. Capsaicin is ideal for this study because it causes a characteristic inflammatory response that is almost always accompanied with pain, has a well-validated dose-response curve, and has effects that will go away completely in a few hours after administration, causing no permanent damage to study subjects. Effects of capsaicin will be measured by changes (decreases) from baseline in thermal and tactile thresholds, as well as by verbally reported cutaneous pain levels (on a scale from 0-10). Participants will also be given study medication in the form of a placebo, one drug, or a combination of drugs before capsaicin injection to allow for any analgesic effects to peak before pain onset. For those receiving active medication, they will either receive Naproxen with placebo or the combination of naproxen and l-dopa (the latter of which will be in one of two different doses). This will allow the investigators to investigate (1) whether co-administration of naproxen and l-dopa has analgesic effects in low levels of acute pain in humans, (2) if this combination is pain-alleviating, whether it is equally as or more efficacious than naproxen, which is the clinical standard of treatment, and finally (3) what dose provides the most analgesia.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must be currently healthy and have none of the exclusion criteria listed below.

• Must be at least 18 years of age.

• Must be able to communicate (speak and write) in English.

• Must demonstrate that they understand what the study entails and requires of them.

• Must be able to dedicate the amount of time (~3 hours) to participate in the study.

Exclusion Criteria:

• History of chronic pain of any kind

• Have a current episode of acute pain of any kind (including stomach ache, headache, muscle ache, etc)

• History of psychiatric illness or brain injury

• History of substance abuse

• History of motor impairments

• History of another chronic disease (such as heart disease, celiac's, bronchial asthma, etc)

• Have a diagnosis of narrow-angle glaucoma

• History or presence of high blood pressure

• History or presence of melanoma cancer

• Currently on a high-protein diet

• Women who are pregnant, trying to get pregnant, or breastfeeding

• Known or suspected allergies to capsaicin, peppers, levodopa, carbidopa, naproxen, NSAIDs, rubbing alcohol (in the medical wipes), or lidocaine

• History or presence of dermatological disorder, including contact dermatitis and a history of skin allergies in general

• Presence of a skin lesion in the areas to be tested

Prohibited Medication:

• Aliskiren

• ACE inhibitors

• Angiotensin 2 receptor blockers

• Cidofovir

• Corticosteroids

• Anti-platelet drugs

• Blood-thinners

• Another NSAID

• MAOIs

• Tetrabenazine

• Anti-depressants

• Anti-psychotics

• Metoclopramide

• Phenytoin

• Papaverine

• Sedatives or muscle relaxers

• Tryptan/L-tryptophan

• DA agonists/antagonists

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Pain

Intervention

Drug:
• Naproxen
Subjects will take one 250mg Naproxen capsule
• Sinemet
Subjects will take one 12.5mg/50mg Sinemet.
• Sinemet
Subjects will take one 25mg/100mg Sinemet.
• Placebo
Subjects will take two placebos.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Northwestern University	National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VAS pain scale		1 Day	No